Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,782 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K. Dang NH, et al. Among authors: sullivan s. Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5. Br J Haematol. 2018. PMID: 28677896 Free PMC article. Clinical Trial. No abstract available.
A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.
Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C. Wagner-Johnston ND, et al. Leuk Lymphoma. 2015;56(10):2863-9. doi: 10.3109/10428194.2015.1017821. Epub 2015 Mar 29. Leuk Lymphoma. 2015. PMID: 25707288 Clinical Trial.
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Among authors: sullivan st. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Tomasson MH, Iida S, Niesvizky R, Mohty M, Bahlis NJ, Martinez-Lopez J, Koehne G, Rodriguez-Otero P, Miles Prince H, Viqueira A, Leip E, Conte U, Sullivan ST, Lesokhin AM. Tomasson MH, et al. Among authors: sullivan st. Hemasphere. 2024 Jul 24;8(7):e136. doi: 10.1002/hem3.136. eCollection 2024 Jul. Hemasphere. 2024. PMID: 39055646 Free PMC article. No abstract available.
Epidermal spongiotic Langerhans cell collections, but not eosinophils, are a clue to the diagnosis of allergic contact dermatitis: A series of 170 clinically- and patch test-confirmed cases.
Wu PA, Wu J, Liu R, Sullivan S, Keller O, Caro-Chang L, Pemba Y, Fung MA. Wu PA, et al. Among authors: sullivan s. J Am Acad Dermatol. 2024 Dec 19:S0190-9622(24)03379-6. doi: 10.1016/j.jaad.2024.11.062. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39709083 Free article.
Asparagus officinalis L. extract exhibits anti-proliferative and anti-invasive effects in endometrial cancer cells and a transgenic mouse model of endometrial cancer.
Fang Z, Kong W, Zhao Z, Sun W, Xu G, Clark LH, Sullivan SA, Tran AQ, Zhou CS, Sun D, Zhao L, Wang J, Zhou C, Bae-Jump VL. Fang Z, et al. Among authors: sullivan sa. Front Pharmacol. 2024 Dec 4;15:1507042. doi: 10.3389/fphar.2024.1507042. eCollection 2024. Front Pharmacol. 2024. PMID: 39697544 Free PMC article.
2,782 results